Insight journal - Technology

Market research analysis: Monoclonal antibody partnering

Posted on 21 July 2014

Tags: , , ,

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years .

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies have monovalent affinity, in that they bind to the same epitope.

According to the Current Agreements life science deals and alliance database, around 550 monoclonal antibody partnering deals have been announced since 2009. The Monoclonal Antibodies Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter monoclonal antibodies partnering deals covering the following types of monoclonal antibodies:

Monoclonal antibodies

o   Murine mAb

o   Chimeric mAb

o   Humanized mAb

o   Human aAb

o   Polyclonal Antibodies

Since 2009, partnering in this technology has been consistent with an average of 112 deals announced in the past five years.

The following figure shows antibody partnering trends frequency between 2009 and June 2014.

Figure 1: Monoclonal antibody partnering by year 2009-2014

1

 

 

 

 

 

 

 

Source: Current Agreements, 2014

According to the database Current Agreementsbig pharma companies are quite active in signing deals involving monoclonal antibody assets. Interest has been growing in recent years where big pharma companies working on oncology drugs partner with biotechnology companies working on monoclonal antibodies.

The primary big pharma companies participating in monoclonal antibody partnering include Sanofi, Johmson & Johnson, Pfizer, Amgen, each with 18 deals and GSK and Roche with 16 and 15 deals respectively announced since 2009.

An example of a deal term entered by Sanofi-Aventis is as follows:

Sanofi-Aventis –Merrimack Pharmaceuticals: Collaborative R&D, licensing and co-promotion agreement for MM-121

Merrimack Pharmaceuticals and Sanofi-aventis announced the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.

Under the terms of the agreement, Sanofi-aventis will make an upfront payment of $60 million and will be responsible for all development costs. Merrimack is eligible for an additional $470 million in milestone payments as well as tiered double-digit royalties on sales of MM-121. Merrimack will execute the development of MM-121 through Phase 2 proof of concept for each indication and sanofi-aventis will be responsible for development thereafter. Merrimack retains the right to co-promote the therapy in the United States.

The most number of clinical trials are announced for human monoclonal antibodies as they are the fastest growing among this category of therapeutics. With discovery stage the most partnered stage of development, this is closely followed by preclinical stage.

Figure 2: Monoclonal antibody partnering by stage of development - 2009-2014

2

 

 

 

 

 

 

 

Source: Current Agreements, 2014

The following figure shows monoclonal antibodies partnering trends by technology type. It is observed that the vast majority or deals are made specifically for humanized mAb and human mAb, showing promise in the development of this emerging technology.

Figure 3: Monoclonal antibodies partnering trends by technology type since 2009

 

  3

 

 

 

 

 

Source: Current Agreements, 2014

As an emerging and exciting area for therapeutic intervention, monoclonal antibody deal making can have a high headline deal value.

The following figure shows the leading monoclonal antibody deals by headline value of the deal when announced between 2009 and 2014.

 Figure 4: Top monoclonal antibodies deals by value since 2009

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

The therapy area where monoclonal antibody deals are mainly focused around is oncology with around 414 deals signed since 2009. The specific cancer therapy  focus are in the following areas: lymphoma, solid tumors, melanoma, colorectal and so on. To view the specific details of the deals with a therapy focus purchase our report Monoclonal Antibodies Partnering Terms and Agreements.

Other therapeutic focus areas in antibody partnering are in infectives and immunology.

 Figure 5: Monoclonal antibodies deals by therapy area 2009-2014

 

 5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Sources

The above information has been abstracted from the following resources:

Shamini Thiagarajan

 

Related

Read: more monoclonal antibody deals in pharma, biotech, life science partnering deal news, insights and glossary

View : glossary definition of monoclonal antibody

ReportMonoclonal Antibody Partnering Terms and Agreements

Related reports: Monoclonal Antibodies Partnering Terms and Agreements ; Antibody Partnering Terms and Agreements

View also: Other technology type reports

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply